How Doctors Determine GLP-1 Dosing: A Guide to Titration Schedules

GLP-1 medications aren't prescribed at full strength from day one. Every patient starts on a low dose and gradually increases — a process called titration. This isn't optional caution; it's evidence-based protocol designed to minimize side effects, improve tolerability, and find the dose where your body responds best.

Here's how doctors determine your dosing schedule and what influences the decisions along the way.

Why Titration Exists

GLP-1 receptor agonists work by mimicking the incretin hormone GLP-1, which slows gastric emptying, reduces appetite, and enhances insulin secretion. These effects are dose-dependent — and so are the side effects. Nausea, the most common complaint, is significantly more prevalent in patients who start at higher doses without gradual escalation.

Titration allows your body to adapt to each dose level before increasing. Clinical trials for both semaglutide and tirzepatide demonstrated that structured titration schedules reduced gastrointestinal side effects by 30–50% compared to starting at therapeutic doses directly.

Standard Titration Schedules

Semaglutide (Ozempic/Wegovy Protocol)

• Weeks 1–4: 0.25mg weekly (initiation dose — not therapeutic)
• Weeks 5–8: 0.5mg weekly
• Weeks 9–12: 1.0mg weekly
• Weeks 13–16: 1.7mg weekly
• Week 17+: 2.4mg weekly (maintenance dose for weight management)

Tirzepatide (Mounjaro/Zepbound Protocol)

• Weeks 1–4: 2.5mg weekly
• Weeks 5–8: 5.0mg weekly
• Weeks 9–12: 7.5mg weekly
• Weeks 13–16: 10mg weekly
• Week 17+: 12.5mg or 15mg weekly (based on response and tolerability)

Factors That Influence Your Dose

Titration isn't one-size-fits-all. Physicians adjust based on several patient-specific factors:

• Side effect severity: Persistent nausea, vomiting, or diarrhea at a given dose may warrant an extended period before the next increase — or holding at the current level.
• Weight-loss response: If you're losing weight steadily at 1.0mg semaglutide, your doctor may hold that dose rather than escalate to 1.7mg.
• Glycemic response: Patients with type 2 diabetes may reach target HbA1c at lower doses than needed for maximum weight loss.
• Kidney or liver function: Impaired organ function can affect drug clearance, potentially requiring slower titration.
• Concurrent medications: Drugs that affect gastric motility or blood sugar may influence dosing decisions.

What Happens When You Hit Your Maintenance Dose

The goal of titration is to reach the lowest effective dose — the point where you're achieving clinically meaningful weight loss (typically ≥5% of body weight) with manageable side effects. Not every patient needs the maximum dose. Some stabilize at intermediate levels with excellent results.

Your provider should reassess at each dose level: How's your appetite? How are side effects? What does the scale show? These check-ins drive dosing decisions — not arbitrary timelines.

Red Flags in Dosing Practices

• Starting at therapeutic dose: Any provider who prescribes 2.4mg semaglutide from day one is skipping evidence-based protocol.
• No check-ins between dose changes: Titration without monitoring isn't titration — it's just a schedule.
• Aggressive escalation despite side effects: Your body's response should guide the pace, not a calendar.
• No option to hold or reduce: A good provider works with you, not through you.